Robert K Blake

US Patent:

6777417, Aug 17, 2004

Filed:

Sep 10, 2002

Appl. No.:

10/238051

Inventors:

Congxin Liang - Sunnyvale CA
Huiping Guan - South San Francisco CA
Peng Cho Tang - Moraga CA
Robert A. Blake - San Carlos CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 31495

US Classification:

51425409, 544373

Abstract:

The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

US Patent:

7154297, Dec 26, 2006

Filed:

Jan 21, 2005

Appl. No.:

10/905832

Inventors:

Rafael C. Camarota - Sunnyvale CA, US
Robert Blake - Saratoga CA, US

Assignee:

Altera Corporation - San Jose CA

International Classification:

H03K 19/177
G06F 7/38

US Classification:

326 40, 326 38, 716 17

Abstract:

Volatility of a programmable logic device (PLD) or field programmable gate array (FPGA) is selectable to be volatile or nonvolatile. In the volatile mode, configuration or other data of the integrated circuit are lost once power is removed from the integrated circuit. In the nonvolatile mode, configuration or other data is retained even when power is removed from the integrated circuit. Upon power-up, in nonvolatile mode, the integrated circuit does not need external data. In an embodiment, the mode, whether volatile or nonvolatile, may be selected during manufacturing. In other embodiment, the mode may be selected by other means, such as by the user.

US Patent:

7620876, Nov 17, 2009

Filed:

Apr 19, 2006

Appl. No.:

11/407519

Inventors:

David Lewis - Toronto, CA
Robert Blake - Saratoga CA, US
Richard G. Cliff - Los Altos CA, US
Srinivas T. Reddy - Fremont CA, US

Assignee:

Altera Corporation - San Jose CA

International Classification:

G11C 29/00

US Classification:

714763, 714725, 714723, 714719, 362 38, 362 39

Abstract:

A device reduces false positive memory error detections by using a masking unit and sensitivity mask data to exclude unused portions of the memory from the error detection computations. A device includes an error detection unit to read data from the memory and verify data integrity. The sensitivity mask data indicates unused portions of the memory. Unused portions of the memory may correspond with configuration data for unused portions of a programmable device. Each bit of the sensitivity mask data may indicate the usage of one or more bits of the data from the memory. In response to the mask data, the masking unit sets data from the unused portions of the memory to values that do not change the result of the error detection computations. This prevents any errors in data from the unused portions of the memory from raising an error signal.

US Patent:

20040266855, Dec 30, 2004

Filed:

Jul 13, 2004

Appl. No.:

10/889050

Inventors:

Congxin Liang - Sunnyvale CA, US
Huiping Guan - Waltham CA, US
Peng Tang - Moraga CA, US
Robert Blake - San Carlos CA, US

Assignee:

SUGEN, INC.

International Classification:

A61K031/404
C 07D 4 3/02

US Classification:

514/414000, 548/455000

Abstract:

The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

US Patent:

20080193438, Aug 14, 2008

Filed:

Mar 10, 2006

Appl. No.:

11/908114

Inventors:

Arthur Brace - Redwood City CA, US
Robert A. Blake - San Carlos CA, US
Lori S. Friedman - San Carlos CA, US
Lynn Margaret Bjerke - Sutton, GB
Kevin M. Ward - San Francisco CA, US

Assignee:

EXELIXIS INC. - South San Francisco CA

International Classification:

A61K 39/395
G01N 33/53
A61P 35/00
C12N 5/00

US Classification:

4241301, 435 72, 435375

Abstract:

Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.

US Patent:

20100122354, May 13, 2010

Filed:

Jun 20, 2006

Appl. No.:

11/993122

Inventors:

Arthur Brace - Redwood City CA, US
Margaret Lynn Bjerke - Surrey, GB
Lori S. Friedman - San Carlos CA, US
Kevin Ward - San Francisco CA, US
Robert A. Blake - San Carlos CA, US

Assignee:

EXELIXIS, INC. - South San Francisco CA

International Classification:

G01N 33/00
C12Q 1/68
G01N 33/53
C12N 5/02
A01K 67/00

US Classification:

800 3, 435 6, 435 71, 435375, 800 8

Abstract:

Human CDC6 genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of CDC6 are provided.

US Patent:

20100183583, Jul 22, 2010

Filed:

Jun 20, 2006

Appl. No.:

11/993191

Inventors:

Arthur Brace - Redwood City CA, US
Margaret Lynn Bjerke - Surrey, GB
Lori S. Friedman - San Carlos CA, US
Kevin Ward - San Francisco CA, US
Robert A. Blake - San Carlos CA, US

Assignee:

EXELIXIS, INC. - South San Francisco CA

International Classification:

A61K 39/395
G01N 33/53
C12Q 1/68
A01K 67/00
C12N 5/02

US Classification:

4241301, 435 71, 435 6, 800 8, 435375

Abstract:

Human GALK1 genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of GALK1 are provided.

US Patent:

20110135629, Jun 9, 2011

Filed:

Jun 20, 2006

Appl. No.:

11/993130

Inventors:

Arthur Brace - Redwood City CA, US
Margaret Lynn Bjerke - Surrey, GB
Lori S. Friedman - San Carlos CA, US
Kevin Ward - San Francisco CA, US
Robert A. Blake - San Carlos CA, US

Assignee:

EXELIXIS, INC. - South San Francisco CA

International Classification:

A61K 39/395
A61K 31/7088
A61P 35/00
C12Q 1/68
C12N 5/00
C12Q 1/48
G01N 33/53

US Classification:

4241301, 514 44 R, 435 613, 435375, 435 15, 435 71

Abstract:

Human MPTENAKT genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of MPTENAKT are provided.